Establishment and Characteristics of a Novel Mantle Cell Lymphoma-derived Cell Line and a Bendamustine-resistant Subline

TOMOKO TAKIMOTO-SHIMOMURA1, HISAO NAGOSHI1,2, SAORI MAEGAWA1, YUTO FUJIBAYASHI1, TAKU TSUKAMOTO1, YAYOI MATSUMURA-KIMOTO1, YOSHIKI MIZUNO1, YOSHIKI CHINEN1, SHINSUKE MIZUTANI1,3, YUI SHIMURA1, SHIGEO HORIIKE1, MASAFUMI TANIWAKI1, TSUTOMU KOBAYASHI1 and JUNYA KURODA1

1Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan; 2Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan; 3The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia

Abstract. Background/Aim: Bendamustine hydrochloride (BH) is a key therapeutic agent for mantle cell lymphoma (MCL), while the mechanism underlying BH-resistance has not been verified. Materials and Methods: We compared molecular/biological characteristics of a newly-generated MCL-derived cell line KPUM-YY1 and its BH-resistant subline KPUM-YY1R. Results: The growth-inhibitory IC50 for BH was 20 μM in KPUM-YY1 cells, while cell proliferation was not inhibited by up to 60 μM BH in KPUM-YY1R cells. Compared to KPUM-YY1 cells, gene expression profiling in KPUM-YY1R cells revealed up-regulation of 312 genes, including ABCB1 encoding P-glycoprotein (P-gp), and microsomal glutathione S-transferase 1 (MGST1). Addition of either a P-gp inhibitor or a GST inhibitor, at least partly, restored sensitivity to BH in KPUM-YY1R cells. In addition, KPUM-YY1R cells showed cross-resistance against various anti-MCL chemotherapeutics. Conclusion: BH resistance is mediated by overlapping mechanisms with overexpression of ABCB1 and MGST1, and is potentially accompanied by multidrug resistance in MCL.

This article is freely accessible online.

Correspondence to: Junya Kuroda, MD, Ph.D. Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan. E-mail: junkuro@koto.kpu-m.ac.jp

Key Words: Mantle cell lymphoma, bendamustine, resistance, ABCB1, MGST1.

Mantle cell lymphoma (MCL) is one of the most difficult-to-treat subtypes of non-Hodgkin’s lymphoma (NHL), despite recent advances in therapeutic strategies, including immunochemotherapy incorporating rituximab (RIT) and genotoxic agents, ibrutinib, bortezomib (BTZ), or high-dose chemotherapy followed by autologous stem cell transplantation (1-4). Amongst various cytotoxic agents, bendamustine hydrochloride (BH) is one of the most promising central drugs in the treatment for MCL. BH exerts an anti-lymphoma effect through complex and overlapping mechanisms, including induction of apoptosis via a DNA-damage stress response, inhibition of mitotic checkpoints, and induction of mitotic catastrophe (5, 6).

In a clinical setting, BH plus rituximab increases progression-free survival (PFS) and has fewer toxic effects than the standard R-CHOP regimen (RIT, cyclophosphamide (CPA), doxorubicin (DOX), and vincristine (VCR)) in previously untreated patients with MCL (5). BH also has clinical activity in patients with relapsed NHL, including those refractory to other alkylating agents and purine analogs (5, 6). However, relapse occurs in most treated cases of MCL (7), and little is known about the mechanisms of resistance to BH. In this study, we investigated the molecular profiles of a novel MCL cell line with acquired BH resistance, with the goal of identifying the mechanism of resistance as a basis for development of a strategy to overcome BH resistance in treatment of MCL.

Materials and Methods

Establishment of cell lines. Primary lymphoma cells were isolated from peripheral blood of a MCL patient with informed consent, and were cultured in RPMI-1640 supplemented with 10% heat-
inactivated fetal bovine serum, 2 mmol/l L-glutamine, and penicillin/streptomycin in a highly humidified atmosphere of 5% CO₂ and 95% air at 37°C. A novel cell line designated as KPUM YY1 was established after continuous culture for several months. KPUM YY1 cells were subjected to continuous exposure to BH with gradual escalation of the concentration up to 50 μM, and a BH-resistant subline KPUM YY1R was established. Subsequently, KPUM YY1R cells were cultured and maintained by passage in a culture medium containing 50 μM BH for over years. A human MCL-derived cell line, Jeko-1, was also used in some of the analyses below. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and with the approval of the institutional ethical review board of Kyoto Prefectural University of Medicine.

Cytogenetic and genome copy number analyses. Double color-fluorescence in situ hybridization (DC-FISH) and spectral karyotyping were performed as described previously (8, 9). The karyotype was described in accordance with the International System for Human Cytogenetic Nomenclature ISCN 2013 (10). Vysis IGH/CCND1 DF FISH and IGH/C-MYC DF FISH probe kits (Abbott Japan, Tokyo, Japan) were utilized for DC-FISH. A DNA gain and loss assay based on a SNP array (GeneChip Human Mapping 6.0 array; Affymetrix, Santa Clara, CA, USA) was performed on genomic DNA purified from KPUM YY1 and KPUM YY1R cells. The CNAG3.5.1 program was used for analysis of SNP array data to determine total copy numbers (11, 12).

Microarray analysis and signal pathway analysis. Comprehensive gene expression analysis was performed to compare gene expression profiles in KPUM YY1 and KPUM YY1R cells, using GeneChip arrays, a GeneChip Scanner 3000, and array data analysis with GeneChip software, v.1.0 (Affymetrix, Santa Clara, CA, USA). Genes with at least a 1.5-fold difference in expression between KPUM YY1 and KPUM YY1R cells were considered positive. For signal pathway analysis, data were analyzed with Ingenuity software (Ingenuity Systems, Mountain View, CA, USA).

Assay for TP53 mutational status. TP53 gene mutational status was analyzed as described elsewhere (13).

Assays for growth inhibition and drug combination. Cells were treated with various concentrations of BH for 96 h, and cytostatine (CA), DOX, etoposide (ETP), MDR1, VCR (Sigma-Aldrich, St. Louis, MO), ibrutinib (Selleck Chemicals, Houston, TX), mofosfamide (the active metabolite of CPA, Santa Cruz Biotechnology, Dallas, TX, USA), lenalidomide (LEN) (Celgene, Summit, NJ), melphalan, or BTZ (provided by the Screening Committee of Anticancer Drugs) for 48 h, and cell viability was evaluated using a modified MTT assay in Cell Counting Kit-8 (Dojindo, Kumamoto, Japan). Cyclosporine A (Wako Pure Chemical Industries, Ltd., Osaka, Japan), verapamil (Sigma-Aldrich), PSC833, and C-4 (Santa Cruz Biotechnology) were utilized as inhibitors for ABCB1, and ethacrynic acid was used as a glutathione-S-transferase (GST) inhibitor (Sigma-Aldrich). Data are shown as the mean±standard error of three independent experiments.

Reverse-transcription-polymerase chain reaction (RT-PCR). RT-PCR analysis was performed as described previously (12), using the following primers: ABCB1-S, 5'-CAC GTG GTT GGA AGC TAA CC-3' and ABCB1-A, 5'-GAA GCC CAG AGC ATA AGA TGC-3' for detection of ABCB1 expression; MGST1-S, 5'-ATT GCC CTC CTT TAG TCC TTG and MGST1-A, TAA TTC CTC TGC TCC CCT CC for detection of MGST1 expression, and β-actin-S, 5'-CTT CTA CAA TGA GCT GCG TG-3' and β-actin-A, 5'-TCATGAGGTAGTCAGTCAGG-3' for detection of β-actin expression as an internal control.

Western blotting. Western blotting was performed as described previously (14), using a mouse monoclonal primary antibody for ABCB1 (D-11 clone; Santa Cruz Biotechnology) and an antibody to β-actin (Sigma-Aldrich) as an internal control.

Results

Establishment and cytogenetic features of KPUM YY1 cells. A 60-year-old male patient was diagnosed with MCL clinical stage IVA in the Ann Arbor staging system. The patient was treated with chemotherapies including R-CHOP, Hyper-CVAD/MTX-CA (CPA, VCR, DOX, dexamethasone (DEX), high-dose methotrexate (MTX) and CA), CHASE (CA, high-dose CA, DEX, ETP), cladribine, BTZ, irinotecan, L-asparaginase, gemcitabine, and BH for repeated relapse and remission, and eventually died of MCL progression after 17 years of treatment. A novel cell line, KPUM YY1, was developed from circulating primary lymphoma cells collected from the patient in the terminal phase. KPUM YY1 cells were morphologically round and medium in size with various forms of deformed nuclei (Figure 1A). These cells were maintained as a suspension culture in conventional culture medium. DC-FISH for KPUM YY1 cells identified the presence of fusion genes of immunoglobulin heavy chain (IGH) and cyclin D1 (Figure 1B) and of IGH and e-MYC (Figure 1C). SKY analyses further revealed that KPUM YY1 cells harbored complex karyotypic abnormalities, including a three-way translocation t(8;14;11)(q24;q32;q13), but not del17p (Figure 1D). This three-way translocation was also observed in patient-derived primary lymphoma cells (Data not shown).

Development of a BH-resistant subline KPUM YY1R and its cytogenetic and molecular characteristics. The patient exhibited clinical resistance to BH, but growth of KPUM YY1 cells was inhibited by BH, with an IC₅₀ of 20 μM in 96-hour treatment in vitro (Figure 2A). To investigate the mechanisms underlying resistance to BH, we sought to establish a BH-resistant subline of KPUM YY1. Continuous exposure to BH with gradual escalation of the BH concentration from 5 to 50 μM for 8 months generated a BH-resistant subline, KPUM YY1R, that was not inhibited by up to 60 μM BH and proliferated at 50.0 μM BH (Figure 2A and B).

To dissect the cytogenetic and molecular characteristics of this subline, including those associated with BH resistance, comparative analyses of cytogenetics and gene expression profiles (GEPs) in KPUM YY1 and KPUM YY1R cells were performed using SKY, genome copy number, and
expression microarray analyses. Several cytogenetic abnormalities were identified in KPUM-YY1R cells that were not present in parental KPUM-YY1 cells in SKY and genome array analyses (Table I, Figure 2C and D). In GEP analyses, 312 genes were up-regulated more than 1.5-fold and 160 genes were down-regulated to less than 0.67-fold in KPUM-YY1R cells compared with KPUM-YY1 cells (Data not shown). Genes upregulated in KPUM-YY1R cells included \textit{ABCB1} (1.79-fold), and the Ingenuity canonical signal pathway analysis based on the GEP results suggested that KPUM-YY1R cells harbored distinct gene expression patterns in the glutathione S-transferase (GST) family, such as \textit{MGST1} (3.23-fold), \textit{GSTA4}, or \textit{GSTM2} (Table II). Indeed, overexpression of \textit{MDR1} and \textit{MGST1} was confirmed by RT-PCR (Figure 2E) and an increase of P-gp was found at the protein level (Figure 2F). Eleven of 472 genes with differential expression in GEP were associated with additional genomic regions identified by SKY and genome copy number analyses in KPUM-YY1R cells (Table I), but none had previously been associated with drug resistance. In addition, TP53 mutation was absent in KPUM-YY1 and KPUM-YY1R cells (data not shown).

\textit{ABCB1} and \textit{MGST1} are involved in resistance to BH in KPUM-YY1R cells. Based on the above results, we focused on the \textit{ABCB1} and GST families as candidate causes of acquisition of resistance to BH in KPUM-YY1R cells. Addition of an inhibitor of \textit{ABCB1} protein (5 μM...
cyclosporine A, 10 μM verapamil, 5 μM PSC833, or 5 μM C-4) partly restored the sensitivity to BH in KPUM-YY1R cells (Figure 3A, B, C and D). Perhaps consistent with faint expression of ABCB1 protein in parental KPUM-YY1 cells (Figure 2F), addition of ABCB1 inhibitors also enhanced the growth inhibitory effect of BH in KPUM-YY1 cells, although the degree of enhancement was much smaller compared with that in KPUM-YY1R cells. Similarly, addition of 30 μM ethacrynic acid, a GST inhibitor, partly restored sensitivity to BH in KPUM-YY1R cells (Figure 3E). These results indicate the functional significance of upregulation of ABCB1 and MGST1 in development of BH resistance in MCL.

Cross-resistance to other chemotherapeutic agents in KPUM-YY1R cells. Compared to parental KPUM-YY1 cells, KPUM-YY1R cells showed partial cross-resistance to DOX, mafosfamide, melphalan, VCR and ibrutinib (Figure 4), whereas sensitivity to cytarabine, ETP, FLU, BTZ, and LEN, which are used in treatment of MCL, were mostly equivalent in the two cell lines (Figure 5).

Discussion

BH is a unique anticancer agent since it structurally consists of three active moieties: an alkylating group, in common with the nitrogen mustard family; a benzimidazole ring, which may act as a purine analog; and a butyric acid sidechain. Therefore, BH may have antitumor effects against various types of cancers. At present, BH is used as a central therapeutic component in both first-line and salvage strategies for various types of low grade B-cell NHLs and for MCL, a usually aggressive and difficult-to-treat disease subtype, in the clinical setting (15-19). Regarding its mechanisms of action, BH alkylates and crosslinks DNA, leading to double-strand breaks (DSBs) followed by p53-dependent and -independent apoptosis in cancer cells, with formation of DSBs that is more powerful and long-lasting than other alkylating agents. In addition, unlike other alkylators, BH can also induce mitotic catastrophe via inhibition of mitotic checkpoint regulators such as polo-like kinase 1, aurora kinase A, or cyclin B1 (6, 17, 20, 21). Due to these overlapping mechanisms, BH has only partial in vitro cross-resistance with other alkylators, such as CPA or melphalan (17), and has full antitumor activity in anthracycline-resistant and platinum-drug resistant cell line (20). These findings may explain the efficacy of BH for both treatment-naïve and relapsed patients with indolent NHL, including those who have lost responsiveness to other alkylating agents or purine analogs (5, 20). In addition, BH has been shown to exert synergistic cytotoxicity with BTK inhibitors on MCL-derived cell lines, implicating its further therapeutic application (22).

The molecular mechanism for resistance to BH has not been investigated as intensively as the mechanism of action. However, acquisition of clinical resistance to BH is a critical event that potentially determines the life expectancy of patients with B-cell NHL, and especially MCL, and there is an urgent need to understand the mechanisms underlying resistance to BH. To answer this question, in this study we developed a novel MCL-derived cell line, KPUM-YY1, and a BH-resistant subline, KPUM-YY1R, by continuous in vitro exposure to BH, and performed comparative analysis of the molecular profiles of these cells. Using this approach, we found that upregulation of ABCB1 and GST, which occurs commonly in drug resistance mechanisms (23), contributed to acquisition of resistance to BH, and we also showed that acquisition of resistance to BH has a potential risk for acquisition of cross-resistance to anti-lymphoma chemotherapeutics such as DOX, mafosfamide, melphalan, and VCR.

Figure 2. Cellular and cytogenetic/molecular characteristics of bendamustine (BH)-resistant KPUM-YY1R cells. A: Growth inhibitory effect of BH on KPUM-YY1 and KPUM-YY1R cells. Cells were treated with BH for 96 h and cell viability was evaluated by a modified MTT assay. Data are shown as means±standard errors from triplicate experiments. Growth of KPUM-YY1 cells was inhibited by BH in a dose-dependent manner, while growth of KPUM-YY1R cells was not inhibited by 60 μM BH. B: Growth curves of KPUM-YY1 and KPUM-YY1R cells. KPUM-YY1R cells were cultured in normal medium, while KPUM-YY1R cells were grown in culture medium containing 50 μM BH. Cells were stained by Trypan Blue and viable cell numbers were counted under an inverted microscope. C: SKY analysis of KPUM-YY1R cells. The representative karyotype of KPUM-YY1R cells is 4n: 84, YY, inv(X)p11q28)x2, der(1)t(1;7)(p32;q11.2), t(2;5)(q21;q5), -2, del(3)(p12)x2, +der(3)(p;13)(q12;14), der(3)7pter→7q22→3q21→13q11→7qter)x2, t(4;14)(q12;q32.1), der(4)t(4;14), der(5)t(5;9)(q11;p13), der(6)t(6;15)(q13;11), der(6)(q;6;8)q25;q42)x2, del(6;20)p21q13)x2, der(7)t?27qter→7q11.2→13q11.2→7pter)x2, t(8;14;11)q24;3q13)x2, del(9)(q9)x21, der(9)t(9p→9q22;13q31;5), -9, -9, der(10)t(10;19)(p15;q13)x2, der(10)5qter→5q15::2q21→2q13::10q11→10qter), t(12;18)(q15;p11)x2, der(12)t(12)(p21p11.2)x2, der(13)t(13;11)(p22;q32)x2, +13, -14, -14, -15, -15, -15, +18, der(19)t(9qter→9q13.1;14q24→1q42;8q24→8qter)x2, -20, -20, -21. Arrows indicate a three-way translocation t(8;14;11)(q24;3q23;13). D: Genome copy number analysis in KPUM-YY1R cells. A DNA gain and loss assay based on a SNP array was performed on genomic DNA purified from KPUM-YY1R cells. The CNAG3.5.1 program was used for analysis of SNP array data to determine total copy numbers. E: RT-PCR analyses for ABCB1 and MGST1. Transcriptional expression of ABCB1 and MGST1 was examined in KPUM-YY1 cells, KPUM-YY1R cells, normal B lymphocytes, and Jeko-1 cells (MCL-derived cell line), β-actin was used as an internal control. F: Western blot for ABCB1 protein. ABCB1 protein expression was examined in KPUM-YY1 cells, KPUM-YY1R cells, normal B lymphocytes, and Jeko-1 cells, with β-Actin used as an internal control.
ABCB1 encodes P-gp, a plasma membrane drug efflux pump that causes resistance to its substrate anticancer agents, such as DOX, VCR, and ETP. Drugs that are potential inducers of P-gp are generally also substrates of this transporter, but recent studies have shown that several agents that are not transportable by P-gp can also induce P-gp overexpression. Moreover, P-gp has effects that are independent of its drug efflux activity, including effects on the function of TP53.

Table I. Comparison of cytogenetic and gene expression analysis between KPUM-YY1 and KPUM-YY1R cells.

| Method              | KPUM-YY1                                                      | KPUM-YY1R                                                      | Differentially expressed genes in GEP                        |
|---------------------|--------------------------------------------------------------|---------------------------------------------------------------|-------------------------------------------------------------|
| SKY                 | der(1)t(1:7)(p32;q11.2) der(5)t(5:9)(q11:p13)                 | ZYG11A, CDKN2C, JUN ANKRD18A                                  | CNTNAP3                                                    |
|                     | der(9)t(9pter→9q22:13:5) der(10)(5qter→5q15:2q21→2q13:10p11+10qter) der(13)t(13p11:p32) |                                               |                                                             |
| Genome Array        | 1p13.3-1p35.1 gain                                          | ZYG11A, IFH44, IFH44L                                       | SORT1, JUN, MANEAL                                         |
|                     | 2q11.2-2q21.2 gain                                          | 3q13.11 gain                                                  | IGI                                                        |
|                     | 4q12-4q22.1 loss                                            | 5q11.1-5q12.1 loss                                            | LYZL1                                                      |
|                     | 10p11.10p13 loss                                            | 10p14 loss                                                   |                                                             |
|                     | 10p15.1-10p15.3 loss                                       | 16q12.2-16q21 loss                                           |                                                             |
|                     | 16q21 loss                                                  | 16q21 mgain                                                  |                                                             |

Table II. Top ingenuity canonical pathways enriched by genes that were significantly differentially up-regulated in KPUM-YY1R cells.

| Ingenuity canonical pathways                                      | -log(p-Value) | Ratio | Molecules                                                                 |
|------------------------------------------------------------------|---------------|-------|---------------------------------------------------------------------------|
| Epithelial adherence junction signaling                           | 2.60E+00      | 5.19E -02 | MAGI1, LMO7, LEF1, TCF3, NOTCH1, ACVR2A, TCF7L2, CTNNB1                  |
| Factors promoting cardiogenesis in vertebrates                   | 2.53E+00      | 6.06E -02 | FZD6, LEF1, MEF2C, TCF3, ACVR2A, TCF7L2                                   |
| Glutathione - mediated detoxification                            | 2.22E+00      | 6.82E -02 | MGST1, GSTM2, GSTA4                                                      |
| Autoimmune thyroid disease signaling                              | 1.79E+00      | 4.84E -02 | CD80, TSHR, CD86                                                         |
| Mouse embryonic stem cell pluripotency                           | 1.71E+00      | 5.05E -02 | ID1, FZD6, LEF1, TCF3, TCF7L2                                            |
| Human embryonic stem cell pluripotency                           | 1.70E+00      | 3.70E -02 | S1PR4, PDGFA, FZD6, LEF1, TCF3, TCF7L2                                    |
| Aryl hydrocarbon receptor signaling                              | 1.66E+00      | 3.51E -02 | MGST1, GSTM2, JUN, NF1A, GSTA4, NRP1                                      |
| Role of Wnt/GSK-3 signaling in the pathogenesis of influenza     | 1.65E+00      | 4.82E -02 | FZD6, LEF1, TCF3, TCF7L2                                                  |
| Type I diabetes mellitus signaling                               | 1.64E+00      | 4.13E -02 | CD3G, CD80, SOCS6, SOCS2, CD86                                           |
| Systemic lupus erythematosus signaling                           | 1.59E+00      | 2.73E -02 | CD3G, RNPC3, JUN, CD80, RNU4 CD86, RNU5A -1                               |
| Basal cell carcinoma signaling                                   | 1.58E+00      | 5.13E -02 | FZD6, LEF1, TCF3, TCF7L2                                                  |
| Thyroid cancer signaling                                         | 1.57E+00      | 6.82E -02 | LEF1, TCF3, TCF7L2                                                        |
| Glutathione redox reactions I                                    | 1.51E+00      | 8.33E -02 | MGST1, GPX7                                                               |
| CD28 signaling in T helper cells                                 | 1.51E+00      | 3.68E -02 | CD3G, PAK1, JUN, CD80, CD86                                               |
| Nur77 signaling in T lymphocytes                                | 1.41E+00      | 4.69E -02 | CD3G, CD80, CD86                                                         |
| TNFR1 signaling                                                 | 1.41E+00      | 5.56E -02 | PAK1, JUN, TNFAP3                                                         |
| CTLA4 signaling in cytotoxic T lymphocytes                       | 1.35E+00      | 4.17E -02 | CD3G, CD80, CD86, PPPN22                                                  |
| Diphthamide biosynthesis                                         | 1.32E+00      | 7.69E -02 | DPH5                                                                      |
survivin, caspases, protein expression, glycosylation and phosphorylation, which may collectively induce changes in cell sensitivity to agents that are not P-gp substrates (24-27). Indeed, BH has not been proven to be a substrate for the P-gp drug efflux pump; therefore, we speculate the possible involvement of drug efflux pump-independent mechanisms for the acquisition of resistance to BH in KPUM-YY1R cells. Irradiation-induced P-gp overexpression has been associated

Figure 3. Effects of inhibitors of ABCB1 and GST on sensitivity to BH in KPUM-YY1 and KPUM-YY1R cells. Cells were treated with BH for 96 h with or without 5 μM cyclosporin A (A), 10 μM verapamil (B), 5 μM PSC833 (C), 5 μM C-4 (D) or 30 μM ethacrynic acid (E). Cell viability was evaluated by a modified MTT assay. Growth inhibition by BH was at least partly reversed by each inhibitor for ABCB1 or GST in KPUM-YY1R cells.
with resistance to BH in colorectal cancer cell lines (28). The pathway through which continuous exposure to BH causes up-regulation of \(ABCB1\) is uncertain, but resistance to BH is at least partly reversed by addition of P-gp antagonists, as for resistance to anthracyclines or vinca alkaloids (29, 30).

Conjugation with glutathione mediated by GSTs is a major route of bendamustine metabolism (31). GSTs are a complex multigene family of enzymes that detoxify electrophilic xenobiotics such as alkylating agents, such that overexpression of GSTs is associated with resistance to...
alkylating agents or anthracyclines. Basic glutathione levels and GST activity showed no correlation to sensitivity to BH in previous studies (20, 32, 33), but we found that inhibition of GSTs partly restored the sensitivity to BH in KPUM-YY1R cells. Thus, we speculate that sensitivity and resistance to BH is associated with the GST level or another effect of GST that is cell- or tumor-dependent. There is no clinically available inhibitor for ABCB1 or GST, which suggests the importance of an appropriate clinical sequence of therapeutic agents for MCL. That is, once resistance to BH is acquired, use of agents with effects unrelated to P-gp or GST might be most rational.

There are some limitations to this study. We first established a parental KPUM-YY1 cell line from a patient with MCL who developed clinical resistance to BH, and it might have been expected that this cell line should also be resistant to BH. However, KPUM-YY1 cells retain sensitivity to various anticancer agents, including BH, in in vitro experiments. The precise reason for this discrepancy is unclear, but we speculate that there are additional mechanisms other than the ABCB1 and GST pathways for clinical resistance to BH in vivo, such as a protective effect of the tumor microenvironment or dysregulation of the pharmacological metabolism. It is also conceivable that the clonal tide during treatment may cause the discrepancy. Given that the patient was first sensitive to BH and then acquired clinical resistance, the BH-resistant clone might have become predominant after long exposure to BH in development of clinical resistance, but there could still be a small residual population of BH-sensitive clones, and the parental KPUM-

Figure 5. Sensitivity of KPUM-YY1 and KPUM-YY1R cells to chemotherapeutic agents. Cells were treated with anticancer agents for 48 h and cell viability was evaluated by a modified MTT assay. There was no significant difference between KPUM-YY1 and KPUM-YY1R cells in sensitivity to (A) cytarabine, (B) etoposide, (C) fludarabine, (D) bortezomib, or (E) lenalidomide.
YY1 cells could have been mostly derived from this population. Regardless, the results showed involvement of ABCB1 and GST family proteins in acquisition of BH-resistance and secondary multidrug resistance in a MCL-derived cell line, but unknown mechanisms may also account for clinical resistance to BH. It will be important to investigate the clinical role of upregulation of ABCB1 or GST family proteins in MCL in a future study.

In conclusion, this study, for the first time, showed that common multidrug resistance mechanisms, such as ABCB1 and GSTs, underlie resistance to BH, and that acquisition of BH resistance potentially leads to multidrug resistance in MCL. The newly-developed KPUM-YY1 and KPUM-YY1R cells allowed identification of multiple mechanisms underlying BH activity and resistance, and may facilitate development of a strategy that overcomes treatment refractoriness in MCL.

Acknowledgements

The Authors are grateful to T. Ikawa and Y. Yamane for their excellent technical assistance. This work was supported in part by a Grant-in-Aid for Scientific Research from The Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT KAKENHI 16K09856) (MT); a Grant-in-Aid for Young Scientists (B) (JSPS KAKENHI Grant Number JP16K21284) (YC); the National Cancer Center Research and Development Fund (29-A-3); a grant (Practical Research for Innovative Cancer Control) from the Japan Agency for Medical Research and Development (AMED) (17ck0106348h0001); and by the Takeda Science Foundation and AstraZeneca (JK).

References

1 Lenz G, Dreyling M, Hoster E, Wörmann B, Dührsen U, Metzner B, Eimermacher H, Neubauer A, Wandt H, Steinhauser H, Martin S, Heidemann E, Aldaoud A, Parwaresch R, Hasford J, Unterhalt M and Hiddemann W: Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23(9): 1984-1992, 2005.

2 Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McCreivy J, Claw F, Buggy JJ, Chang BY, Beapure DM, Kunkel LA and Ogawa H, Martin S, Heidemann E, Aldaoud A, Parwaresch R, Hasford J, Unterhalt M and Hiddemann W: Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23(9): 1984-1992, 2005.

3 Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, Pylypenko H, Verhofg E, Siritanaratkul N, Osmanov E, Alexeeva J, Pereira J, Drach J, Mayer J, Hong X, Okamoto R, Pei L, Rooney B, van de Velde H Cavalli F and LYM-3002 Investigators: Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med 372(10): 944-953, 2015.
14 Nagoshi H, Taki T, Chinen Y, Takteawa S, Tsukamoto T, Maegawa S, Yamamoto-Sugitani M, Tsutsumi Y, Kobayashi T, Matsumoto Y, Horiike S, Okuno Y, Fujiwara S, Hata H, Kuroda J and Taniwaki M: Transcriptional dysregulation of the deleted in colorectal carcinoma gene in multiple myeloma and monoclonal gammopathy of undetermined significance. Genes Chromosomes Cancer 54(12): 788-795, 2015.

15 Rummel MJ, Al-Butran SE, Kim SZ, Welslau M, Hecker R, Kofahl-Krause D, Josten KM, Rost A, Neise M, von Grünhagen U, Chow KU, Hansmann ML, Hoelzer D and Mitrou PS: Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J Clin Oncol 23(15): 3383-3389, 2005.

16 Robinson KS, Williams ME, van der Jagt RH, Cohen P, Herst JA, Tulpule A, Schwartzberg LS, Lemieux B and Cheson BD: Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma. J Clin Oncol 26(27): 4473-4479, 1984.

17 Leoni LM, Bailey B, Reifert J, Bendall HH, Zeller RW, Corbel J, Elliott G and Niemeyer CC: Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 14(1): 309-317, 2008.

18 Kalaycio M: Bendamustine: a new look at an old drug. Cancer 115(3): 473-479, 2009.

19 Montillo L, Ricci F, Tedeschi A, Vismara E and Morra E: Bendamustine: new perspective for an old drug in lymphoproliferative disorders. Expert Rev Hematol 3(2): 131-148, 2010.

20 Strumberg D, Harstrick A, Doll K, Hoffmann B and Seeker S: Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 7(4): 415-421, 1996.

21 Gaul L, Mandl-Weber S, Baumann P, Emmerich B and Schmidtmaier R: Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways. J Cancer Res Clin Oncol 134(2): 245-253, 2008.

22 Hagiwara K, Tokunaga T, Iida H and Nagai H: Synergistic cytotoxicity of bendamustine and the BTK inhibitor in a mantle cell lymphoma cell line. Anticancer Res 35(12): 6679-6684, 2015.

23 Rolland D, Raharjouma N, Barbarat A, Houlgatte R and Thielement C: Inhibition of GST-pi nuclear transfer increases mantle cell lymphoma sensitivity to cisplatin, cytarabine, gemcitabine, bortezomib and doxorubicin. Anticancer Res 30(10): 3951-3957, 2010.

24 He S, Liu F, Xie Z, Xu X, Wu W and Jiang Y: P-Glycoprotein/MDR1 regulates pologene transcription through p53 expression in human breast cancer cells. Int J Mol Sci 11(9): 3309-3351, 2010.

25 Rueli AA, Tainton KM, Darcy PK, Smyth MJ and Johnstone RW: P-glycoprotein inhibits caspase-8 activation but not formation of the death inducing signal complex (disc) following Fas ligation. Cell Death Differ 9(11): 1266-1272, 2002.

26 Bubencikova T, Cholujová D, Messingerová L, Mislovicova D, Seres M, Breier A and Sulova Z: Detection of glycomic alterations induced by overexpression of p-glycoprotein on the surfaces of L1210 cells using sialic acid binding lectins. Int J Mol Sci 13(11): 15177-15192, 2012.

27 Breier A, Gibalova L, Seres M, Barancik M and Sulova Z: New insight into p-glycoprotein as a drug target. Anticancer Agents Med Chem 13(1): 159-170, 2013.

28 Bottke D, Koychev D, Busse A, Heufelder K, Wiegel T, Thiel E, Hinkelbein W and Keilholz U: Fractionated irradiation can induce functionally relevant multidrug resistance gene and protein expression in human tumor cell lines. Radiat Res 170(1): 41-48, 2008.

29 Nobili S, Landini I, Gigliioni B and Mini E: Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 7(7): 861-879, 2006.

30 Kim YK, Song YJ, Seo DW, Kang DW, Lee HY, Rhee DK, Han JW, Ahn CM, Lee S and Kim SN: Reversal of multidrug resistance by 4-chloro-N-(3-((E)-3-(4-hydroxy-3-methoxy-phenyl)acryloyl)phenyl)benzamide through the reversible inhibition of P-glycoprotein. Biochem Biophys Res Commun 355(1): 136-142, 2007.

31 Teichert J, Sohr R, Baumann F, Hennig L, Merkle K, Caca K and Preiss R: Synthesis and characterization of some new phase II metabolites of the alkylator bendamustine and their identification in human bile, urine, and plasma from patients with cholangiocarcinoma. Drug Metab Dispos 33(7): 984-992, 2005.

32 Bennaceur-Griscelli A, Bosq J, Koscielny S, Lefrère F, Turhan A, Brousse N, Hermine O and Ribrag V: High level of glutathione-S-transferases and Chemotherapy Resistance of Hodgkin’s Lymphoma Cell Lines. Anticancer Res 30(10): 3905-3915, 2016.